Heart Failure

As part of the 2020 Year in Review, Cardiology Today compiled a list of selected drugs and devices related to the specialty that were newly approved or cleared or were granted a new indication. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omissions. Appearance of a drug or device does not constitute any endorsement by Cardiology Today, its editors, publisher or editorial board. – The Editors

Ferric carboxymaltose vs. placebo in iron-deficient patients with acute HF.

Patients with HF and COVID-19 had high risk for complications, with nearly 1 in 4 dying during hospitalization, researchers reported.

As little as one alcoholic drink per day may confer elevated risk for development of atrial fibrillation, regardless of age and other CV risk factors, according to a study published in the European Heart Journal.

Healio and Cardiology Today have curated a list of the top news of 2020 in diabetes and the heart.

Among patients with an implanted cardioverter defibrillator, risk for appropriate ICD interventions and death varied by disease subtype, according to findings from the UMBRELLA study.

Older women who received early breast cancer treatment with anthracycline experienced fewer HF hospitalizations associated with the cardiotoxic effects of chemotherapy when also exposed to statin therapy, researchers reported.

In a national private health care database, age, male sex and comorbidities increased risk for death in patients hospitalized with COVID-19, according to data presented at the virtual American Heart Association Scientific Sessions.

Healio and Cardiology Today have aggregated the latest news from the FDA.

The MyROAD pre-recorded audio instruction card for at-home care and self-management improved 30-, 45- and 90-day clinical outcomes in patients following HF hospitalization.